Ezogabine

CHEMBL41355 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

303.3 g/mol

LogP

2.8

Phase

4

This anticonvulsant opens specific potassium channels in neurons to stabilize overactive brain cells and reduce the frequency of seizures. It was used as an add-on treatment for partial-onset seizures in adults with epilepsy.

Masse moléculaire

303,3300 g/mol

LogP

2,80

TPSA

76,40 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Infectious Disease Respiratory Disease Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Major Depressive Disorder Cardiovascular Disease

Mécanisme d'action

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N

InChI

InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)

Molecular Formula

C16H18FN3O2

HBD / HBA

3 / 5

Liaisons Rotatives

6

Atomes Lourds

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This anticonvulsant opens specific potassium channels in neurons to stabilize overactive brain cells and reduce the frequency of seizures. It was used as an add-on treatment for partial-onset seizures in adults with epilepsy.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Ezogabine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL41355. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 121892. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Ezogabine sur PillFYI

Structure

Données Clés

Formule: C16H18FN3O2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.